Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4128-4134

  Knudsen, Lotte Bjerre ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUGON; BIM 51077; CJC 1131; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PREPROGLUCAGON; UNCLASSIFIED DRUG; ZP 10; ZP10;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RISK BENEFIT ANALYSIS; SHORT SURVEY; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH EMPTYING; TACHYPHYLAXIS;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843121153     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030630m     Document Type: Short Survey

References (48)

1. Nauck, M. A.; Kleine, N.; Orskov, C.; Holst, J. J.; Willms, B.; Creutzfeldt, W. Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide-1 (7-36 Amide) in Type-2 (Non-Insulin-Dependent) Diabetic-Patients. Diabetologia 1993, 36, 741-744.
2. Vilsboll, T.; Krarup, T.; Madsbad, S.; Holst, J. J. No Reactive Hypoglycaemia in Type 2 Diabetic Patients after Subcutaneous Administration of GLP-1 and Intravenous Glucose. Diabetic Med. 2001, 18, 144-149.
3. Gromada, J.; Holst, J. J.; Rorsman, P. Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-Like Peptide 1. Pfluegers Arch. 1998, 435, 583-594.
4. Holz, G. G.; Kühtreiber, W. M.; Habener, J. F. Pancreatic Beta-Cells Are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1(7-37). Nature 1993, 361, 362-365.
5. Drucker, D. J.; Philippe, J.; Mojsov, S.; Chick, W. L.; Habener, J. F. Glucagon-Like Peptide I Stimulates Insulin Gene Expression and Increases Cyclic AMP Levels in a Rat Islet Cell Line. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 3434-3438.
6. Bulotta, A.; Hui, H.; Anastasi, E.; Bertolotto, C.; Boros, L. G.; Di Mario, U.; Perfetti, R. Cultured Pancreatic Ductal Cells Undergo Cell Cycle Re-Distribution and Beta-Cell-Like Differentiation in Response to Glucagon-Like Peptide-1. J. Mol. Endocrinol. 2002, 29, 347-360.
7. Egan, J. M.; Bulotta, A.; Hui, H.; Perfetti, R. GLP-1 Receptor Agonists Are Growth and Differentiation Factors for Pancreatic Islet Beta Cells. Diabetes/Metab. Res. Rev. 2003, 19, 115-123.
8. Stoffers, D. A.; Kieffer, T. J.; Hussain, M. A.; Drucker, D. J.; Bonner-Weir, S.; Habener, J. F.; Egan, J. M. Insulinotropic Glucagon-Like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein IDX-1 and Increase Islet Size in Mouse Pancreas. Diabetes 2000, 49, 741-748.
9. Orskov, C.; Holst, J. J.; Nielsen, O. V. Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach. Endocrinology 1988, 123, 2009-2013.
10. Wettergren, A.; Schjoldager, B.; Mortensen, P. E.; Myhre, J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man. Dig. Dis. Sci. 1993, 38, 665-673.
11. Flint, A.; Raben, A.; Astrup, A.; Holst, J. J. Glucagon-Like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J. Clin. Invest. 1998, 101, 515-520.
12. Zander, M.; Madsbad, S.; Madsen, J. L.; Holst, J. J. Effect of 6-Week Course of Glucagon-Like Peptide 1 on Glycaemic Control, Insulin Sensitivity, and Beta-Cell Function in Type 2 Diabetes: A Parallel-Group Study. Lancet 2002, 359, 824-830.
13. Kieffer, T. J.; Habener, J. F. The Glucagon-Like Peptides. Endocr. Rev. 1999, 20, 876-913.
14. Gros, R.; You, X.; Baggio, L. L.; Kabir, M. G.; Sadi, A. M.; Mungrue, I. N.; Parker, T. G.; Huang, Q.; Drucker, D. J.; Husain, M. Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor. Endocrinology 2003, 144, 2242-2252.
15. During, M. J.; Cao, L.; Zuzga, D. S.; Francis, J. S.; Fitzsimons, H. L.; Jiao, X.; Bland, R. J.; Klugmann, M.; Banks, W. A.; Drucker, D. J.; Haile, C. N. Glucagon-Like Peptide-1 Receptor Is Involved in Learning and Neuroprotection. Nat. Med. 2003, 9, 1173-1179.
16. Toft-Nielsen, M. B.; Madsbad, S.; Holst, J. J. Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2001, 86, 3853-3860.
17. Thorens, B. Expression Cloning of the Pancreatic Beta Cell Receptor for the Gluco-Incretin Hormone Glucagon-Like Peptide 1. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8641-8645.
18. 2-Terminus in Type II Diabetic Patients and in Healthy Subjects. Diabetes 1995, 44, 1126-1131.
19. Deacon, C. F.; Pridal, L.; Klarskov, L.; Olesen, M.; Holst, J. J. Glucagon-Like Peptide 1 Undergoes Differential Tissue-Specific Metabolism in the Anesthetized Pig. Am. J. Physiol. 1996, 271, E458-E464.
20. Vilsboll, T.; Agerso, H.; Krarup, T.; Holst, J. J. Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects. J. Clin. Endocrinol. Metab. 2003, 88, 220-224.
21. Larsen, J.; Hylleberg, B.; Ng, K.; Damsbo, P. Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 H/Day To Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment. Diabetes Care 2001, 24, 1416-1421.
22. Nauck, M. A.; Heimesaat, M. M.; Orskov, C.; Holst, J. J.; Ebert, R.; Creutzfeldt, W. Preserved Incretin Activity of Glucagon-Like Peptide-1 [7-36 Amide] but Not of Synthetic Human Gastric-Inhibitory Polypeptide in Patients eith Type-2 Diabetes-Mellitus. J. Clin. Invest. 1993, 91, 301-307.
23. Vilsboll, T.; Krarup, T.; Deacon, C. F.; Madsbad, S.; Holst, J. J. Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes 2001, 50, 609-613.
24. Toft-Nielsen, M. B.; Damholt, M. B.; Madsbad, S.; Hilsted, L. M.; Hughes, T. E.; Michelsen, B. K.; Holst, J. J. Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. J. Clin. Endocrinol. Metab. 2001, 86, 3717-3723.
25. Vilsboll, T.; Krarup, T.; Madsbad, S.; Holst, J. J. Defective Amplification of the Late Phase Insulin Response to Glucose by GIP in Obese Type II Diabetic Patients. Diabetologia 2002, 45, 1111-1119.
26. Unger, R. H.; Orci, L. The Essential Role of Glucagon in the Pathogenesis of Diabetes Mellitus. Lancet 1975, 1, 14-16.
27. Brand, C. L.; Jorgensen, P. N.; Svendsen, I.; Holst, J. J. Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits. Diabetes 1996, 45, 1076-1083.
28. DeFronzo, R. A.; Bonadonna, R. C.; Ferrannini, E. Pathogenesis of NIDDM. A Balanced Overview. Diabetes Care 1992, 15, 318-368.
29. Montrose-Rafizadeh, C.; Yang, H.; Rodgers, B. D.; Beday, A.; Pritchette, L. A.; Eng, J. High Potency Antagonists of the Pancreatic Glucagon-Like Peptide-1 Receptor. J. Biol. Chem. 1997, 272, 21201-21206.
30. Hupe-Sodmann, K.; McGregor, G. P.; Bridenbaugh, Göke, R.; Göke, B.; Thole, H.; Zimmermann, B.; Voigt, K. Characterisation of the Processing by Human Neutral Endopeptidase 24.11 of GLP-1(7-36) Amide and Comparison of the Substrate Specificity of the Enzyme for Other Glucagon-Like Peptides. Regul. Pept. 1995, 58, 149-156.
31. Edwards, C. M. B.; Stanley, S. A.; Davis, R.; Brynes, A. E.; Frost, G. S.; Seal, L. J.; Ghatei, M. A.; Bloom, S. R. Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E155-E161.
32. Doyle, M. E.; Theodorakis, M. J.; Holloway, H. W.; Bernier, M.; Greig, N. H.; Egan, J. M. The Importance of the Nine-Amino Acid C-Terminal Sequence of Exendin-4 for Binding to the GLP-1 Receptor and for Biological Activity. Regul. Pept. 2003, 114, 153-158.
33. Adelhorst, K.; Hedegaard, B. B.; Knudsen, L. B.; Kirk, O. Structure-Activity Studies of Glucagon-Like Peptide-1. J. Biol. Chem. 1994, 269, 6275-6278.
34. Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J. Dipeptidyl Peptidase IV Resistant Analogues of Glucagon-Like Peptide-1 Which Have Extended Metabolic Stability and Improved Biological Activity. Diabetologia 1998, 41, 271-278.
35. Parker, J. C.; Andrews, K. M.; Rescek, D. M.; Massefski, W.; Andrews, G. C.; Contillo, L. G.; Stevenson, R. W.; Singleton, D. H.; Suleske, R. T. Structure-Function Analysis of a Series of Glucagon-Like Peptide-1 Analogs. J. Pept. Res. 1998, 52, 398-409.
36. Stoffers, D. A.; Desai, B. M.; DeLeon, D. D.; Simmons, R. A. Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat. Diabetes 2003, 52, 734-740.
37. Egan, J. M.; Meneilly, G. S.; Elahi, D. Effects of 1-Mo Bolus Subcutaneous Administration of Exendin-4 in Type 2 Diabetes. Am. J. Physiol. 2003, 284, E1072-E1079.
38. Kolterman, O. G.; Buse, J. B.; Fineman, M. S.; Gaines, E.; Heintz, S.; Bicsak, T. A.; Taylor, K.; Kim, D.; Aisporna, M.; Wang, Y.; Baron, A. D. Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2003, 88, 3082-3089.
39. Elbrond, B.; Jakobsen, G.; Larsen, S.; Agerso, H.; Jensen, L. B.; Rolan, P.; Sturis, J.; Hatorp, V.; Zdravkovic, M. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects. Diabetes Care 2002, 25, 1398-1404.
40. Knudsen, L. B.; Nielsen, P. F.; Huusfeldt, P. O.; Johansen, N. L.; Madsen, K.; Pedersen, F. Z.; Thogersen, H.; Wilken, M.; Agerso, H. Potent Derivatives of Glucagon-Like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration. J. Med. Chem. 2000, 43, 1664-1669.
41. Kim, J. G.; Baggio, L. L.; Bridon, D. P.; Castaigne, J. P.; Robitaille, M. F.; Jette, L.; Benquet, C.; Drucker, D. J. Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate-The Ability To Activate the Glucagon- Like Peptide 1 Receptor in Vivo. Diabetes 2003, 52, 751-759.
42. Petersen, J. S.; Thorkildsen, C.; Lundgren, K.; Neve, S. ZP10: A New GLP-1 Agonist That Prevents Diabetes Progression and Increases Insulin MRNA Expression in Db/Db Mice. Diabetologia 2002, 45, A147.
43. Dong, J. Z.; Shen, Y.; Zhang, J.; Taylor, J. E.; Woon, C.; Morgan, B.; Skinner, S.; Cawthorne, M.; Culler, M.; Moreau, J. Design and Synthesis of a Novel GLP-1 Analog, BIM-51077, Which Has Significantly Improved in Vivo Activity. Biopolymers 2003, 71, 391.
44. Shechter, Y.; Tsubery, H.; Fridkin, M. [2-Sulfo-9-fluorenyl- methoxycarbonyl](3)-Exendin-4. A Long-Acting Glucose-Lowering Prodrug. Biochem. Biophys. Res. Commun. 2003, 305, 386-391.
45. Fineman, M. S.; Bicsak, T. A.; Shen, L. Z.; Taylor, K.; Gaines, E.; Varns, A.; Kim, D.; Baron, A. D. Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients with Type 2 Diabetes. Diabetes Care 2003, 26, 2370-2377.
46. Agerso, H.; Jensen, L. B.; Elbrond, B.; Rolan, P.; Zdravkovic, M. The Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of NN2211, a New Long-Acting GLP-1 Derivative, in Healthy Men. Diabetologia 2002, 45, 195-202.
47. Chang, A. M.; Jakobsen, G.; Sturis, J.; Smith, M. J.; Bloem, C. J.; An, B.; Galecki, A.; Halter, J. B. The GLP-1 Derivative NN2211 Restores Beta-Cell Sensitivity to Glucose in Type 2 Diabetic Patients after a Single Dose. Diabetes 2003, 52, 1786-1791.
48. Yamamoto, H.; Kishi, T.; Lee, C. E.; Choi, B. J.; Fang, H.; Hollenberg, A. N.; Drucker, D. J.; Elmquist, J. K. Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites. J. Neurosci. 2003, 23, 2939-2946.